PET for Drug Development and Evaluation, Vol. 26

Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations. The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs. Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas.

The book contains predominantly black-and-white illustrations, with some color illustrations.

Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations.
The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs.
Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas.

Booknews

Explains how positron emission tomography can be used to trace the effect of a drug on a variety of patients' metabolic parameters, or follow the fate in vivo of a compound and so visualize its binding to specific receptors and study directly the mechanisms of drug action in normal and pathological situations. Describes how the imaging technique can contribute to many aspects of drug development, such as conception, toxicity, pharmacokinetics and metabolism, clinical research, and the relation between clinical and biological effects. Of interest to professionals in the pharmaceutical industry and to regulatory authorities who assess data on new drugs. Possibly a conference proceedings, since the chapters are in various type faces and there is no index. Annotation c. Book News, Inc., Portland, OR (booknews.com)

Comar, D. (Hopital Neuro-cardiologique, Lyon)

The contributors represent the specialties of clinical neuroscience, psychiatry, and oncologic diagnosis. Most are from hospitals, universities, and research institutions in the U.K., the U.S., the Netherlands, and Sweden. Institutions prominently represented include Hammersmith Hospital and Karolinska Institute.